Virtual cell model could accelerate protein-degrader therapy design

Weill Cornell Medicine researchers have created a computer model to expedite the development of protein-degrader therapies, a cutting-edge treatment method showing significant promise for cancer treatment. While most drugs utilize small molecules to neutralize disease-causing proteins, protein-degrader therapies aim to eradicate the target protein entirely.

This approach may offer several benefits over inhibiting a protein, such as eliminating proteins with cancer-linked mutations or those produced in excessive quantities. By utilizing the body's existing cellular machinery, targeted protein degradation redirects it to eliminate unwanted proteins, as explained by senior author Dr. Olivier Elemento.

The team developed a framework to optimize the design of degraders that effectively destroy the target protein. Traditionally, protein degrader development relied on time-consuming trial and error. However, lead author Dr. Wei Du created a mathematical model to simplify the process by identifying suitable protein targets and mapping cost-effective optimization routes.

The model uses readily available laboratory measurements, enabling scientists to observe potential degrader behavior within a computerized cell model. Dr. Du noted that even proteins with slow turnover can undergo significant degradation when bound by relatively weak degraders, suggesting that this model could streamline the development of targeted therapies.

This innovation could prove particularly valuable in treating cancer-causing mutations, where proteins may have vastly increased quantities in cancerous cells. As various treatment modalities become available, including gene and mRNA therapies, the need for mathematical modeling tools to guide the selection of the most suitable approach for individual patients will also increase.

The researchers hope to continue refining methods to accelerate the design and testing of therapies, ultimately working towards highly personalized, precision medicine tailored to each patient's unique cancer mutations.